Genotypic and Phenotypic Comparisons of de Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7900-7906

  Hazlehurst, Lori A ^a   Enkemann, Steven A ^a   Beam, Craig A ^a   Argilagos, Raul F ^a   Painter, Jeffrey ^a   Shain, Kenneth H ^a   Saporta, Sara ^a   Boulware, David ^a   Moscinski, Lynn ^a   Alsina, Melissa ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CHOLESTEROL; DNA; MELPHALAN;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL ADHESION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; FANCONI ANEMIA; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CASPASES; CELL ADHESION; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FIBRONECTINS; GENE EXPRESSION PROFILING; HUMANS; ISOENZYMES; MELPHALAN; MITOCHONDRIA; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 10744227500     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dalton, W. S., and Salmon, S. E. Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol. Oncol. Clin. North Am., 6: 383-393, 1992.
2. Kyle, R. A., Pajak, T. F., Henderson, E. S., Nawabi, I. U., Brunner, K., Henry, P. H., McIntyre, O. R., and Holland, J. F. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer Treat. Rep., 66: 451-456, 1982.
3. Bellamy, W. T., Dalton, W. S., Gleason, M. C., Grogan, T. M., and Trent, J. M. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res., 51: 995-1002, 1991.
4. Gottesman, M. M., Fojo, T., and Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2: 48-58, 2002.
5. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E. I. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Wash. DC), 247: 1457-1460, 1990.
6. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93: 1658-1667, 1999.
7. Hazlehurst, L. A., Damiano, J. S., Buyuksalm, I., Pledger, W. J., and Dalton, W. S. Adhesion to fibronectin regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 38: 4319-4327, 2000.
8. Hazlehurst, L. A., Valkov, N., Wisner, L., Storey, J. A., Boulware, D., Sullivan, D. M., and Dalton, W. S. Reduction in drug-induced DNA double strand-breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 98: 1897-1903, 2001.
9. Damiano, J. S., Hazlehurst, L. A., and Dalton, W. S. Cell adhesion mediated resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma radiation. Leukemia (Balt.), 15: 1232-1239, 2001.
10. Hoyt, D. G., Rusnak, J. M., Mannix, R. J., Modzelewski, R. A., Johnson, C. S., and Lazo, J. S. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured marine tumor-derived endothelial cells. Cancer Res., 56: 4146-4149, 1996.
11. Aoudjit, F., and Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene, 20: 4995-5004, 2001.
12. Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Streiter, R., and Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med., 5: 662-668, 1999.
13. Hanks, S. K., Calab, M. B., Harper, M. C., and Patel, S. K. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell spreading on fibronectin. Proc. Natl. Acad. Sci. USA, 89: 8487-8491, 1992.
14. Lin, T. H., Aplin, A. E., Shen, Y., Chen, Q., Schaller, M., Romer, L., Aukhil, I., and Juliano, R. L. Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J. Cell Biol., 136: 1385-1395, 1997.
15. Meng, F., and Lowell, C. A. A β1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. EMBO J., 17: 4391-4403, 1998.
16. Meredith, J. E., Jr., Fazeli, B., and Schwartz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell, 4: 953-961, 1993.
17. Shain, K. H., Landowski, T. H., and Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol., 168: 2544-2553, 2002.
18. Krajewska, M., Wang, H. G., Krajewski, S., Zapata, J. M., Shabaik, A., Gascoyne, R., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res., 57: 1605-1613, 1997.
19. Kent, C. R., Eady, J. J., Ross, G. M., and Steel, G. G. The comet moment as measure of DNA damage in the comet assay. Int. J. Radiat. Biol., 67: 655-660, 1995.
20. Tipnis, S. R., Blake, D. G., Shepherd, A. G., and McLellan, L. I. Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance. Biochem. J., 337 (Pt. 3): 559-566, 1999.
21. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
22. Bouillet, P., Metcalf, D., Huang, D. C., Tarlinton, D. M., Kay, T. W., Kontgen, F., Adams, J. M., and Strasser, A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (Wash. DC), 286: 1735-1738, 1999.
23. Ishida, R., and Buchwald, M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res., 42: 4000-4006, 1982.
24. Siddique, M. A., Nakanishi, K., Taniguchi, T., Grompe, M., and D'Andrea, A. D. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Exp. Hematol., 29: 1448-1455, 2001.
25. Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M. S., Timmers, C., Hejna, J., Grompe, M., and D'Andrea, A. D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell, 7: 249-262, 2001.
26. Reinhold, W. C., Kouros-Mehr, H., Kohn, K. W., Maunakea, A. K., Lababidi, S., Roschke, A., Stover, K., Alexander, J., Pantazis, P., Miller, L., Liu, E., Kirsch, I. R., Urasaki, Y., Pommier, Y., and Weinstein, J. N. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res., 63: 1000-1011, 2003.
27. Landowski, T. H., Olashaw, N. E., Agrawal, D., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene. 22: 2417-2421, 2003.
28. Soma, M. R., Baetta, R., De Renzis, M. R., Mazzini, G., Davegna, C., Magrassi, L., Butti, G., Pezzotta, S., Paoletti, R., and Fumagalli, R. In vivo enhanced antitumor activity of carmustine [N,N′ -bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res., 55: 597-602, 1995.
29. van de Donk, N. W., Kamphuis, M. M., Lokhorst, H. M., and Bloem, A. C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia (Balt.), 16: 1362-1371, 2002.